EMBECTA CORP. Revenue
EMBECTA CORP. (EMBC) reported Revenue of $271.70 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-07
- EMBECTA CORP. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $271.70M, a 8.05% decline year-over-year.
- EMBECTA CORP. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $221.80M, a 14.36% decline year-over-year.
- EMBECTA CORP. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $261.20M, a 0.27% decline year-over-year.
- EMBECTA CORP. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $264.00M, a 7.72% decline year-over-year.
- EMBECTA CORP. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $1.08B, a 3.80% decline from fiscal 2024.
- EMBECTA CORP. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $1.12B, a 0.21% increase from fiscal 2023.
- EMBECTA CORP. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $1.12B, a 0.77% decline from fiscal 2022.
- EMBECTA CORP. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $1.13B, a 3.07% decline from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $271.70M 10-Q · filed 2026-08-07 | $493.50M derived: sum of 2 quarters · filed 2026-08-07 | $754.70M 10-Q · filed 2026-08-07 | $1.02B derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $221.80M 10-Q · filed 2026-05-05 | $483.00M 10-Q · filed 2026-05-05 | $747.00M derived: sum of 3 quarters · filed 2026-05-05 | $1.04B derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $261.20M 10-Q · filed 2026-02-05 | $525.20M derived: sum of 2 quarters · filed 2026-02-05 | $820.70M derived: sum of 3 quarters · filed 2026-08-07 | $1.08B derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-09-30 | $264.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | $559.50M derived: sum of 2 quarters · filed 2026-08-07 | $818.50M derived: sum of 3 quarters · filed 2026-08-07 | $1.08B 10-K · filed 2025-11-25 |
| 2025-06-30 | $295.50M 10-Q · filed 2026-08-07 | $554.50M derived: sum of 2 quarters · filed 2026-08-07 | $816.40M 10-Q · filed 2026-08-07 | $1.10B derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $259.00M 10-Q · filed 2026-05-05 | $520.90M 10-Q · filed 2026-05-05 | $807.00M derived: sum of 3 quarters · filed 2026-05-05 | $1.08B derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $261.90M 10-Q · filed 2026-02-05 | $548.00M derived: sum of 2 quarters · filed 2026-02-05 | $820.50M derived: sum of 3 quarters · filed 2026-02-05 | $1.11B derived: sum of 4 quarters · filed 2026-02-05 |
| 2024-09-30 | $286.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | $558.60M derived: sum of 2 quarters · filed 2025-11-25 | $845.80M derived: sum of 3 quarters · filed 2025-11-25 | $1.12B 10-K · filed 2025-11-25 |
| 2024-06-30 | $272.50M 10-Q · filed 2025-08-08 | $559.70M derived: sum of 2 quarters · filed 2025-08-08 | $837.00M 10-Q · filed 2025-08-08 | $1.12B derived: sum of 4 quarters · filed 2025-11-25 |
| 2024-03-31 | $287.20M 10-Q · filed 2025-05-09 | $564.50M 10-Q · filed 2025-05-09 | $846.40M derived: sum of 3 quarters · filed 2025-11-25 | $1.13B derived: sum of 4 quarters · filed 2025-11-25 |
| 2023-12-31 | $277.30M 10-Q · filed 2025-02-06 | $559.20M derived: sum of 2 quarters · filed 2025-11-25 | $845.30M derived: sum of 3 quarters · filed 2025-11-25 | $1.12B derived: sum of 4 quarters · filed 2025-11-25 |
| 2023-09-30 | $281.90M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | $568.00M derived: sum of 2 quarters · filed 2025-11-25 | $845.10M derived: sum of 3 quarters · filed 2025-11-25 | $1.12B 10-K · filed 2025-11-25 |
| 2023-06-30 | $286.10M 10-Q · filed 2024-08-09 | $563.20M derived: sum of 2 quarters · filed 2024-08-09 | $838.90M 10-Q · filed 2024-08-09 | $1.11B derived: sum of 4 quarters · filed 2024-12-11 |
| 2023-03-31 | $277.10M 10-Q · filed 2024-05-09 | $552.80M 10-Q · filed 2024-05-09 | $827.40M derived: sum of 3 quarters · filed 2024-12-11 | $1.12B derived: sum of 4 quarters · filed 2024-12-11 |
| 2022-12-31 | $275.70M 10-Q · filed 2024-02-09 | $550.30M derived: sum of 2 quarters · filed 2024-12-11 | $841.40M derived: sum of 3 quarters · filed 2024-12-11 | $1.12B derived: sum of 4 quarters · filed 2024-12-11 |
| 2022-09-30 | $274.60M derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-11 | $565.70M derived: sum of 2 quarters · filed 2024-12-11 | $840.20M derived: sum of 3 quarters · filed 2024-12-11 | $1.13B 10-K · filed 2024-12-11 |
| 2022-06-30 | $291.10M 10-Q · filed 2023-08-08 | $565.60M derived: sum of 2 quarters · filed 2023-08-08 | $854.90M 10-Q · filed 2023-08-08 | $1.16B derived: sum of 4 quarters · filed 2023-11-29 |
| 2022-03-31 | $274.50M 10-Q · filed 2023-05-12 | $563.80M 10-Q · filed 2023-05-12 | $864.60M derived: sum of 3 quarters · filed 2023-11-29 | $1.16B derived: sum of 4 quarters · filed 2023-11-29 |
| 2021-12-31 | $289.30M 10-Q · filed 2023-02-14 | $590.10M derived: sum of 2 quarters · filed 2023-11-29 | $885.10M derived: sum of 3 quarters · filed 2023-11-29 | $1.17B derived: sum of 4 quarters · filed 2023-11-29 |
| 2021-09-30 | $300.80M derived: 10-K 12 month − 10-Q 9 month · filed 2023-11-29 | $595.80M derived: sum of 2 quarters · filed 2023-11-29 | $880.00M derived: sum of 3 quarters · filed 2023-11-29 | $1.17B 10-K · filed 2023-11-29 |
| 2021-06-30 | $295.00M 10-Q · filed 2022-08-15 | $579.20M derived: sum of 2 quarters · filed 2022-08-15 | $864.50M 10-Q · filed 2022-08-15 | |
| 2021-03-31 | $284.20M 10-Q · filed 2022-05-13 | $569.50M 10-Q · filed 2022-05-13 | ||
| 2020-09-30 | $1.09B 10-K · filed 2022-12-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| Orthofix Medical Inc. (OFIX) | $0.373B | ||
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |